BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10356	Companies
215519	Keywords
145328	Articles
114169	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 11/04/2025 at 09:05, 6 months 2 days ago

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia

BioNxt Solutions Inc. European Patent Office MS Treatment Sublingual Thin-Film Global Patent Coverage
BRIEF

published on 10/30/2025 at 08:10, 6 months 7 days ago

BioNxt Solutions Inc. fait progresser un brevet pour l'administration de médicaments anticancéreux

Sclérose En Plaques Solutions BioNxt Administration De Médicaments Brevet Eurasien Stratégie En Matière De Brevets
BRIEF

published on 10/30/2025 at 08:10, 6 months 7 days ago

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
PRESS RELEASE

published on 10/30/2025 at 08:05, 6 months 7 days ago

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO
BRIEF

published on 10/21/2025 at 09:10, 6 months 16 days ago

BioNxt Initiates Sublingual Cladribine Study for MS Treatment Optimization

Multiple Sclerosis Bioavailability Drug Delivery Bioequivalence Study Sublingual Cladribine
BRIEF

published on 10/21/2025 at 09:10, 6 months 16 days ago

BioNxt lance une étude sur la cladribine sublinguale pour optimiser le traitement de la sclérose en plaques

Sclérose En Plaques Biodisponibilité Étude De Bioéquivalence Administration De Médicaments Cladribine Sublinguale
PRESS RELEASE

published on 10/21/2025 at 09:05, 6 months 16 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 6 months 28 days ago

BioNxt Solutions aborde le vote de l'assemblée générale annuelle en pleine grève postale

Assemblée Générale Annuelle Vote Campagne De Marketing Grève De Postes Canada Soumission Par Procuration
BRIEF

published on 10/10/2025 at 01:55, 6 months 28 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 6 months 28 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options

Accesswire

Published on 05/07/2026 at 02:00, 2 hours 16 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 4 hours 46 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 5 hours 11 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 5 hours 16 minutes ago

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/06/2026 at 22:10, 6 hours 6 minutes ago

Banyan Gold Announces Closing of $46.5 Million Private Placement

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 04:00, 15 minutes ago

L’Université chinoise de Hong Kong (CUHK) se classe en tête à Hong Kong et en Asie dans le dernier classement mondial des universités par discipline publié par QS (Quacquarelli Symonds)
Published on 05/07/2026 at 04:00, 15 minutes ago

CUHK Claims Top Positions in Hong Kong and Asia in the Latest QS World University Rankings by Subject
Published on 05/07/2026 at 03:50, 25 minutes ago

450 MHz LTE: Stronger, Smarter Grid for Brazil
Published on 05/07/2026 at 00:47, 3 hours 29 minutes ago

Blue Cap AG expands portfolio through the acquisition of Janoschka AG
Published on 05/07/2026 at 00:43, 3 hours 32 minutes ago

EQS-Adhoc: Blue Cap AG Acquires Janoschka AG and Adjusts Forecast Due to Transaction

Les Echos

Published on 05/06/2026 at 18:00, 10 hours 15 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 10 hours 15 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 10 hours 16 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 18:00, 10 hours 16 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2026
Published on 05/06/2026 at 17:45, 10 hours 31 minutes ago

Information concerning the total number of voting rights and shares 2026 04 30

View all LES ECHOS COMFI WIRE